Drug intelligence / Profile preview

STI-0529

Development stage
Unknown
Lead developer
Sublimity Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

STI-0529 (also known as CyCol) is an oral, colon-targeted formulation of cyclosporine developed by Sublimity Therapeutics. It utilizes the proprietary SmPill delivery technology, which consists of minispheres designed to release the active ingredient specifically in the colon. This localized delivery approach aims to treat moderate to severe ulcerative colitis by providing high concentrations of cyclosporine at the site of inflammation while minimizing systemic exposure and the associated toxicities, such as nephrotoxicity and hypertension. Cyclosporine acts as a calcineurin inhibitor, suppressing T-cell activation and the subsequent production of pro-inflammatory cytokines.

Brand names
CyCol
Other names
CyCol
02

Targets

MPTP (Mitochondrial permeability transition pore)ABCB1 (P-glycoprotein)PPIA (Peptidyl-prolyl cis-trans isomerase A)CN (Calcineurin)

Beyond the preview

Go deeper on STI-0529.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on STI-0529.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call